HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Watanabe, Y. Articles by Tobe, R. Search for Related Content PubMed PubMed Citation Articles by Watanabe, Y. Articles by Tobe, R.

Semiquantitative In Vitro Binding Assay of Indium-111-Labeled Monoclonal Antibodies to Human Cancer and Normal Tissues

Department of Nuclear Medicine, First Department of Surgery and Pathology, Kyoto University Hospital, Kyoto 606, Japan

Correspondence: For reprints contact: Yuji Watanabe, MD, Dept. of Nuclear Medicine, Kyoto University Hospital, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606, Japan.

ABSTRACT

We have developed a simple in vitro method for the semi quantitative assessment of the radiolabeled antibody binding to cancer and normal tissues. Indium-111-labeled F(ab')₂ fragments of 17-1A and 19-9 monoclonal antibodies with well-characterized specificity for gastrointestinal cancer demonstrated similar binding properties between cultured cancer cells and membrane fractions of homogenates prepared from tumor tissues. All of the 17 colon cancer specimens and seven (64%) of 11 gastric cancer specimens obtained by surgery showed positive binding with 17-1A. Specific binding of 19-9 was observed in 9 (53%) colon cancers and 4 (36%) gastric cancers. However, some normal colon tissues were also positive with ¹¹¹In-labeled 17-1A. Relative levels of CA 19-9 antigen expression, determined by the binding with radiolabeled antibodies, correlated with percent positive cells determined by the immunohistochemical assays. Furthermore, membrane fractions could be cryopreserved without losing antibody-binding activity. These results indicate that this assay can be used for testing the immunoreactivity of radiolabeled anti-tumor antibodies and in vitro binding properties to cancer and normal tissues.